ArticleMacromolecular bioscience2025
Mallotus philippensis Extract-Infused Locust Bean Gum-Based Ternary Hydrogel: A Green Fabrication Approach for the Controlled Release of Levofloxacin.
Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mallotus philippensis Extract-Infused Locust Bean Gum-Based Ternary Hydrogel: A Green Fabrication Approach for the Controlled Release of Levofloxacin.Macromolecular bioscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Smart and responsive drug delivery systems are key to next-generation biomedical therapies, offering precision and targeted action. This study reports the development of a novel biodegradable, pH-sensitive, and highly swellable hydrogel composed of locust bean gum, polyvinylpyrrolidone, chitosan, and (3-aminopropyl)triethoxysilane (APTES) as a crosslinker, incorporating Mallotus philippensis (MP) extract to enhance bioactivity. Structural, thermal, and morphological properties were characterized by FT-IR, TGA, and SEM. Swelling behaviour confirmed pH responsiveness, while gel content and biodegradation assays verified stability and degradability. Contact angle and porosity analyses showed favourable surface wettability and porous architecture. Antimicrobial activity demonstrated inhibition of bacterial strains, with cytocompatibility supported by brine shrimp lethality assay. Levofloxacin (LVX) was loaded into hydrogels with and without MP extract, achieving drug encapsulation efficiencies of 89% and 85%, respectively, with a slight decrease attributed to phytoconstituents interactions affecting network density. Drug release profiling at pH 5.5, 6.5, and 7.4 showed sustained release exceeding 80% within 3 h per USP standards. LPC-3AT and LPC-3AT-MP 400 released 87.04% and 94.5% LVX over 180 min in PBS, following a non-Fickian (anomalous) transport mechanism (diffusion exponent n = 0.62). These findings highlight the hydrogel's promise as an injectable platform for controlled drug delivery and advanced biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.